Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Fulvestrant and the sequential endocrine cascade for advanced breast cancer

Tools
- Tools
+ Tools

Johnston, S. (2004) Fulvestrant and the sequential endocrine cascade for advanced breast cancer. BRITISH JOURNAL OF CANCER, 90 (Supple). S15-S18. ISSN 0007-0920

[img]
Preview
PDF
A1962PV.pdf

Download (84kB) | Preview
Official URL: http://www.nature.com/bjc/journal/v90/n1s/full/660...

Abstract

Fulvestrant and the sequential endocrine cascade for advanced breast cancer Following relapse on endocrine therapy for advanced, hormone receptor-positive breast cancer, it is common for patients to experience responses to alternative endocrine agents. Fulvestrant ('Faslodex') is a new type of endocrine treatment - an oestrogen receptor (ER) antagonist with no agonist effects. Fulvestrant downregulates cellular levels of the ER resulting in decreased expression of the progesterone receptor. This unique mode of action means that it is important that fulvestrant is placed optimally within the sequence of endocrine therapies to ensure that. patients gain maximum benefit. Fulvestrant has shown efficacy when used after progression on tamoxifen or anastrozole in postmenopausal women with advanced breast cancer. After progression on fulvestrant, subsequent endocrine treatments can produce responses in many patients, demonstrating that fulvestrant does not lead to crossresistance with other endocrine therapies. Responses to fulvestrant have also been observed in patients heavily pretreated with prior endocrine therapy. Fulvestrant is a versatile endocrine agent that may be integrated into the therapeutic sequence prior to, or subsequent to, other hormonal therapies, and represents a valuable additional antioestrogen for the treatment of postmenopausal women with advanced breast cancer.

Item Type: Article
Authors (ICR Faculty only): Johnston, Stephen
All Authors: Johnston, S.
Uncontrolled Keywords: breast cancer; endocrine therapy; sequencing; fulvestrant; 'Faslodex' Term estrogen deprivation; postmenopausal women; randomized trial; tamoxifen; anastrozole; therapy; cells; receptor; hypersensitivity; antiestrogen
Research teams: Clinical Units > Breast Unit
Depositing User: EPrints Services
Date Deposited: 10 Aug 2007 20:49
Last Modified: 17 Dec 2014 11:33
URI: http://publications.icr.ac.uk/id/eprint/1962

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust